[en] BACKGROUND AND PURPOSE: Leptin, an adipokine synthesized by the placenta during pregnancy, has been proposed for the management of preterm labour (PTL), as it is able to prevent in vitro uterine contractility and remodelling associated with labour onset. Another common feature of labour onset is the phenotypic switch of myometrial smooth muscle cells from a proliferative to a hypertrophic state. As proliferative effects have been demonstrated for leptin in other tissues, we aimed to investigate its ability to induce myometrial proliferation and thus to maintain uterine quiescence. EXPERIMENTAL APPROACH: We stimulated human primary myometrial smooth muscle cells with leptin in the presence or absence of receptor antagonists or signalling pathway inhibitors. KEY RESULTS: Leptin induced myometrial cell proliferation in a biphasic manner. At 6.25 ng · mL(-1), leptin-induced proliferation was mediated by the leptin receptor and required the early activation of ERK1/2. At a concentration above 25 ng · mL(-1), leptin induced direct non-specific stimulation of the IL-6 receptor, leading to NF-κB activation, and exerted anti-proliferative effects. However, at 50 ng · mL(-1), leptin re-induces proliferation via IL-6 receptor stimulation that requires STAT3 and delayed ERK1/2 activation. CONCLUSIONS AND IMPLICATIONS: These data bring new insights into leptin signalling-induced myometrial proliferation and its interrelationship with the IL-6/IL-6 receptor axis. In the light of our previous work, the present study emphasizes the potential value of leptin in the pharmacological management of PTL and it also strengthens the hypothesis that leptin might be a contributory factor in the parturition-related disorders observed in obese women.
Disciplines :
Geriatrics
Author, co-author :
Barrichon, Marina; INSERM, U866, Equipe labellisée ligue contre le Cancer and Association pour la ; Université de Bourgogne, Dijon, France.
Hadi, Tarik; INSERM, U866, Equipe labellisée ligue contre le Cancer and Association pour la ; Université de Bourgogne, Dijon, France.
Wendremaire, Maeva; INSERM, U866, Equipe labellisée ligue contre le Cancer and Association pour la ; Université de Bourgogne, Dijon, France. ; Centre Hospitalier Universitaire de Dijon, Dijon, France.
Ptasinski, Clémentine; INSERM, U866, Equipe labellisée ligue contre le Cancer and Association pour la ; Université de Bourgogne, Dijon, France.
Seigneuric, Renaud; INSERM, U866, Equipe labellisée ligue contre le Cancer and Association pour la ; Université de Bourgogne, Dijon, France.
Marcion, Guillaume ; Université de Liège - ULiège > GIGA > GIGA I3 - Hematology ; INSERM, U866, Equipe labellisée ligue contre le Cancer and Association pour la ; Université de Bourgogne, Dijon, France.
Delignette, Marc; Clinique Sainte-Marthe, Dijon, France.
Marchet, Jacques; Clinique Sainte-Marthe, Dijon, France.
Dumas, Monique; INSERM, U866, Equipe labellisée ligue contre le Cancer and Association pour la ; Université de Bourgogne, Dijon, France. ; Centre Hospitalier Universitaire de Dijon, Dijon, France.
Sagot, Paul; Centre Hospitalier Universitaire de Dijon, Dijon, France. ; Service de Gynécologie & Obstétrique, Dijon, France.
Bardou, Marc; INSERM, U866, Equipe labellisée ligue contre le Cancer and Association pour la ; Université de Bourgogne, Dijon, France. ; Centre Hospitalier Universitaire de Dijon, Dijon, France. ; INSERM CIC-P 803, Dijon, France.
Garrido, Carmen; INSERM, U866, Equipe labellisée ligue contre le Cancer and Association pour la ; Université de Bourgogne, Dijon, France. ; Anti-cancer Center George-François Leclerc, Dijon, France.
Lirussi, Frédéric; INSERM, U866, Equipe labellisée ligue contre le Cancer and Association pour la ; Université de Bourgogne, Dijon, France. ; Centre Hospitalier Universitaire de Dijon, Dijon, France.
Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic receptors. Br J Pharmacol 170: 1676-1705.
Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
Arrowsmith S, Wray S, Quenby S, (2011). Maternal obesity and labour complications following induction of labour in prolonged pregnancy. Brit J Obstet Gynaec 118: 578-588.
Baeuerle PA, Henkel T, (1994). Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12: 141-179.
Bajoria R, Sooranna SR, Ward BS, Chatterjee R, (2002). Prospective function of placental leptin at maternal-fetal interface. Placenta 23: 103-115.
Caüzac M, Czuba D, Girard J, Hauguel-de Mouzon S, (2003). Transduction of leptin growth signals in placental cells is independent of JAK-STAT activation. Placenta 24: 378-384.
Cedergren MI, (2004). Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstet Gynecol 103: 219-224.
Chen C, Chang YC, Liu TP, Chang KJ, Guo IC, (2007). Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway. Endocr Relat Cancer 14: 513-529.
Chen RJ, Ho YS, Guo HR, Wang YJ, (2008). Rapid activation of Stat3 and ERK1/2 by nicotine modulates cell proliferation in human bladder cancer cells. Toxicol Sci 104: 283-293.
Christiaens I, Zaragoza DB, Guilbert L, Robertson SA, Mitchell BF, Olson DM, (2008). Inflammatory processes in preterm and term parturition. J Reprod Immunol 79: 50-57.
Chu SY, Kim SY, Schmid CH, Dietz PM, Callaghan WM, Lau J, et al. (2007). Maternal obesity and risk of cesarean delivery: a meta-analysis. Obesity Rev 8: 385-394.
Cnattingius S, Villamor E, Johansson S, Edstedt Bonamy AK, Persson M, Wikström AK, et al. (2013). Maternal obesity and risk of preterm delivery. JAMA 309: 2362-2370.
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. (1996). Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334: 292-295.
Denison FC, Price J, Graham C, Wild S, Liston WA, (2008). Maternal obesity, length of gestation, risk of postdates pregnancy and spontaneous onset of labour at term. Brit J Obstet Gynaec 115: 720-725.
Domali E, Messinis IE, (2002). Leptin in pregnancy. J Matern Fetal Neonatal Med 12: 222-230.
Fenton JI, Hursting SD, Perkins SN, Hord NG, (2006). Interleukin-6 production induced by leptin treatment promotes cell proliferation in an Apc (Min/+) colon epithelial cell line. Carcinogenesis 27: 1507-1515.
Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitani Y, Yamaguchi T, et al. (1996). Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 5: 449-460.
Gertler A, Elinav E, (2014). Novel superactive leptin antagonists and their potential therapeutic applications. Curr Pharm Des 20: 659-665.
Grimm S, Bauer MK, Baeuerle PA, Schulze-Osthoff K, (1996). Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis. J Cell Biol 134: 13-23.
Grivennikov SI, Karin M, (2010). Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21: 11-19.
Hadi T, Barrichon M, Mourtialon P, Wendremaire M, Garrido C, Sagot P, et al. (2013). Biphasic Erk1/2 activation sequentially involving Gs and Gi signaling is required in beta3-adrenergic receptor-induced primary smooth muscle cell proliferation. Biochim Biophys Acta 1833: 1041-1051.
Hardie L, Trayhurn P, Abramovich D, Fowler P, (1997). Circulating leptin in women: a longitudinal study in the menstrual cycle and during pregnancy. Clin Endocrinol (Oxf) 47: 101-106.
Harris RB, (2014). Direct and indirect effects of leptin on adipocyte metabolism. Biochim Biophys Acta 1842: 414-423.
Hendler I, Goldenberg RL, Mercer BM, Iams JD, Meis PJ, Moawad AH, et al. (2005). The Preterm Prediction Study: association between maternal body mass index and spontaneous and indicated preterm birth. Am J Obstet Gynecol 192: 882-886.
Henson MC, Swan KF, O'Neil JS, (1998). Expression of placental leptin and leptin receptor transcripts in early pregnancy and at term. Obstet Gynecol 92: 1020-1028.
Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M, (1999). NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19: 2690-2698.
Horiguchi A, Oya M, Marumo K, Murai M, (2002). STAT3, but not ERKs, mediates the IL-6-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int 61: 926-938.
Huang F, Xiong X, Wang H, You S, Zeng H, (2010). Leptin-induced vascular smooth muscle cell proliferation via regulating cell cycle, activating ERK1/2 and NF-κB. Acta Biochim Biophys Sin (Shanghai) 42: 325-331.
Khatibi A, Brantsaeter AL, Sengpiel V, Kacerovsky M, Magnus P, Morken NH, et al. (2012). Prepregnancy maternal body mass index and preterm delivery. Am J Obstet Gynecol 207: e211-e217.
Kitawaki J, Koshiba H, Ishihara H, Kusuki I, Tsukamoto K, Honjo H, (2000). Expression of leptin receptor in human endometrium and fluctuation during the menstrual cycle. J Clin Endocrinol Metab 85: 1946-1950.
Levy DE, Lee CK, (2002). What does Stat3 do? J Clin Invest 109: 1143-1148.
Liu Y, Lv L, Xiao W, Gong C, Yin J, Wang D, et al. (2011). Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation. J Huazhong Univ Sci Technol 31: 365-370.
Liu ZJ, Bian J, Liu J, Endoh A, (2007). Obesity reduced the gene expressions of leptin receptors in hypothalamus and liver. Hormone Metab Res 39: 489-494.
MacIntyre DA, Lee YS, Migale R, Herbert BR, Waddington SN, Peebles D, et al. (2014). Activator protein 1 is a key terminal mediator of inflammation-induced preterm labor in mice. FASEB J 28: 2358-2368.
Magarinos MP, Sanchez-Margalet V, Kotler M, Calvo JC, Varone CL, (2007). Leptin promotes cell proliferation and survival of trophoblastic cells. Biol Reprod 76: 203-210.
McDonald SD, Han Z, Mulla S, Beyene J, Knowledge Synthesis G, (2010). Overweight and obesity in mothers and risk of preterm birth and low birth weight infants: systematic review and meta-analyses. BMJ 341: c3428.
Meloche S, Pouyssegur J, (2007). The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26: 3227-3239.
Misra VK, Trudeau S, (2011). The influence of overweight and obesity on longitudinal trends in maternal serum leptin levels during pregnancy. Obesity 19: 416-421.
Morales-Prieto DM, Ospina-Prieto S, Chaiwangyen W, Weber M, Holters S, Schleussner E, et al. (2013). Intranuclear crosstalk between extracellular regulated kinase1/2 and signal transducer and activator of transcription 3 regulates JEG-3 choriocarcinoma cell invasion and proliferation. ScientificWorldJournal 2013: 259845.
Morimoto S, Nabata T, Koh E, Shiraishi T, Fukuo K, Imanaka S, et al. (1991). Interleukin-6 stimulates proliferation of cultured vascular smooth muscle cells independently of interleukin-1 beta. J Cardiovasc Pharmacol 17 (Suppl. 2): S117-S118.
Moynihan AT, Hehir MP, Glavey SV, Smith TJ, Morrison JJ, (2006). Inhibitory effect of leptin on human uterine contractility in vitro. Am J Obstet Gynecol 195: 504-509.
Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
Sagawa N, Yura S, Itoh H, Mise H, Kakui K, Korita D, et al. (2002). Role of leptin in pregnancy-a review. Placenta 23 (Suppl. A): S80-S86.
Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, et al. (2007). Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67: 2497-2507.
Senaris R, Garcia-Caballero T, Casabiell X, Gallego R, Castro R, Considine RV, et al. (1997). Synthesis of leptin in human placenta. Endocrinology 138: 4501-4504.
Sharma D, Saxena NK, Vertino PM, Anania FA, (2006). Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer 13: 629-640.
Shpilman M, Niv-Spector L, Katz M, Varol C, Solomon G, Ayalon-Soffer M, et al. (2011). Development and characterization of high affinity leptins and leptin antagonists. J Biol Chem 286: 4429-4442.
Sinha MK, Opentanova I, Ohannesian JP, Kolaczynski JW, Heiman ML, Hale J, et al. (1996). Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin Invest 98: 1277-1282.
Smith R, (2007). Parturition. N Engl J Med 356: 271-283.
Suzuki TJKT, Ajima R, Nakamura T, Yoshida Y, Yamamoto T, (2002). Phosphorylation of three regulatory serines of Tob by Erk1 and Erk2 is required for Ras-mediated cell proliferation and transformation. Genes Dev 16: 1356-1370.
Tanfin Z, Leiber D, Robin P, Oyeniran C, Breuiller-Fouche M, (2011). Endothelin-1: physiological and pathological roles in myometrium. Int J Biochem Cell Biol 43: 299-302.
Toth KG, McKay BR, De Lisio M, Little JP, Tarnopolsky MA, Parise G, (2011). IL-6 induced STAT3 signalling is associated with the proliferation of human muscle satellite cells following acute muscle damage. PLoS ONE 6: e17392.
Wendremaire M, Bardou M, Peyronel C, Hadi T, Sagot P, Morrison JJ, et al. (2011). Effects of leptin on lipopolysaccharide-induced myometrial apoptosis in an in vitro human model of chorioamnionitis. Am J Obstet Gynecol 205: e361-e369.
Wendremaire M, Mourtialon P, Goirand F, Lirussi F, Barrichon M, Hadi T, et al. (2013). Effects of leptin on lipopolysaccharide-induced remodeling in an in vitro model of human myometrial inflammation. Biol Reprod 88: 45.
Wuntakal R, Hollingworth T, (2010). Leptin-a tocolytic agent for the future? Med Hypotheses 74: 81-82.
Yang WH, Liu SC, Tsai CH, Fong YC, Wang SJ, Chang YS, et al. (2013). Leptin induces IL-6 expression through OBRl receptor signaling pathway in human synovial fibroblasts. PLoS ONE 8: e75551.
Yu CK, Teoh TG, Robinson S, (2006). Obesity in pregnancy. Brit J Obstet Gynaec 113: 1117-1125.